WEBSITE BSE:535217 NSE: HPC BIO Inc. Year: 2002 Industry: Agriculture
Last updated: 00:00
HPC Biosciences Ltd is a biotechnology company that focuses on the discovery and development of innovative drugs for the treatment of various diseases. The company specializes in the fields of oncology, immunology, and inflammation, using advanced technologies and scientific expertise to develop small molecule therapeutics and biologics. HPC Biosciences is committed to advancing the development of novel drug candidates by conducting rigorous research, leveraging strategic partnerships, and utilizing cutting-edge technologies. The company's por...Read More
HPC Biosciences Ltd is a biotechnology company that focuses on the discovery and development of innovative drugs for the treatment of various diseases. The company specializes in the fields of oncology, immunology, and inflammation, using advanced technologies and scientific expertise to develop small molecule therapeutics and biologics. HPC Biosciences is committed to advancing the development of novel drug candidates by conducting rigorous research, leveraging strategic partnerships, and utilizing cutting-edge technologies. The company's portfolio includes several drug candidates that are in various stages of preclinical and clinical development. Overall, HPC Biosciences is dedicated to improving patient outcomes and advancing the field of biotechnology through innovative drug discovery and development. ...Read Less
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Market Cap ₹410 Cr.
Stock P/E 350.4
P/B 12.5
Current Price ₹25.7
Book Value ₹ 2.1
Face Value 1
52W High ₹0
Dividend Yield 0%
52W Low ₹ 0
Price goes above X
Price falls below X
PE goes above X
PE falls below X
₹ | |
| #(Fig in Cr.) | Sep 2013 | Sep 2016 | Sep 2017 |
|---|---|---|---|
| Net Sales | 1 | 1 | 1 |
| Other Income | 0 | 0 | 0 |
| Total Income | 1 | 1 | 1 |
| Total Expenditure | -0 | 0 | 0 |
| Operating Profit | 1 | 1 | 1 |
| Interest | 0 | 0 | 0 |
| Depreciation | 1 | 0 | 0 |
| Exceptional Income / Expenses | 0 | 0 | 0 |
| Profit Before Tax | 0 | 0 | 0 |
| Provision for Tax | 0 | 0 | 0 |
| Profit After Tax | 0 | 0 | 0 |
| Adjustments | -0 | -0 | -0 |
| Profit After Adjustments | 0 | 0 | 0 |
| Adjusted Earnings Per Share | 0 | 0 | 0 |
| #(Fig in Cr.) | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 0 | 3 | 5 | 3 | 3 | 2 | 2 | 2 | 2 | 1 | 2 | 3 |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Income | 0 | 3 | 5 | 4 | 3 | 2 | 2 | 2 | 2 | 1 | 2 | 3 |
| Total Expenditure | 0 | -0 | 0 | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 1 | 0 |
| Operating Profit | -0 | 3 | 4 | 3 | 2 | 2 | 2 | 1 | 1 | 1 | 2 | 3 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | -0 | 3 | 3 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 0 |
| Provision for Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Tax | -0 | 3 | 3 | 1 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 0 |
| Adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Adjustments | -0 | 3 | 3 | 1 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 0 |
| Adjusted Earnings Per Share | -0 | 0.9 | 0.2 | 0.1 | 0 | 0 | 0 | 0 | 0 | 0 | 0.1 | 0 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 100% | 0% | 0% | 0% |
| Operating Profit CAGR | 100% | 26% | 0% | 0% |
| PAT CAGR | 0% | 0% | 0% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | 0% | -1% | -0% | -4% |
| ROE Average | 4% | 2% | 2% | 15% |
| ROCE Average | 4% | 2% | 2% | 15% |
| #(Fig in Cr.) | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shareholder's Funds | 0 | 5 | 28 | 29 | 30 | 30 | 31 | 31 | 31 | 32 | 33 |
| Minority's Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Borrowings | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Total Liabilities | 0 | 5 | 28 | 29 | 30 | 30 | 31 | 31 | 32 | 32 | 33 |
| Fixed Assets | 0 | 1 | 11 | 10 | 8 | 7 | 6 | 5 | 4 | 4 | 3 |
| Other Non-Current Assets | 0 | 0 | 6 | 6 | 4 | 4 | 4 | 4 | 4 | 4 | 4 |
| Total Current Assets | 0 | 4 | 11 | 13 | 17 | 19 | 21 | 22 | 24 | 25 | 26 |
| Total Assets | 0 | 5 | 28 | 29 | 30 | 30 | 31 | 31 | 32 | 32 | 33 |
| #(Fig in Cr.) | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 |
| Cash Flow from Operating Activities | -0 | -0 | 3 | 4 | 0 | -0 | 1 | 0 | 1 | 1 | 1 |
| Cash Flow from Investing Activities | 0 | -1 | -23 | -5 | 1 | 0 | -2 | -0 | -1 | -1 | 0 |
| Cash Flow from Financing Activities | 0 | 2 | 20 | 0 | -0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Cash Inflow / Outflow | -0 | 0 | 1 | -0 | 0 | -0 | -1 | -0 | 0 | 0 | 1 |
| Closing Cash & Cash Equivalent | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 2 |
| # | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | -0.01 | 0.87 | 0.19 | 0.08 | 0.04 | 0.03 | 0.03 | 0.01 | 0.03 | 0.02 | 0.07 |
| CEPS(Rs) | -0.01 | 0.91 | 0.27 | 0.16 | 0.13 | 0.12 | 0.09 | 0.07 | 0.08 | 0.06 | 0.11 |
| DPS(Rs) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Book NAV/Share(Rs) | 0.49 | 1.37 | 1.72 | 1.79 | 1.84 | 1.87 | 1.91 | 1.93 | 1.96 | 1.99 | 2.06 |
| Core EBITDA Margin(%) | 0 | 109.61 | 90.31 | 73.68 | 64.61 | 93.83 | 60.86 | 48.54 | 75.32 | 72.26 | 70.83 |
| EBIT Margin(%) | 0 | 105.16 | 62.57 | 36.29 | 24.46 | 27.44 | 25.2 | 12.33 | 36.17 | 29.94 | 52.14 |
| Pre Tax Margin(%) | 0 | 105.16 | 62.57 | 36.28 | 24.45 | 27 | 25.03 | 11.9 | 36.07 | 29.92 | 52.12 |
| PAT Margin (%) | 0 | 105.16 | 62.52 | 35.7 | 22.78 | 24.65 | 22.48 | 10.12 | 34.63 | 28.06 | 51.16 |
| Cash Profit Margin (%) | 0 | 109.61 | 90.41 | 74.96 | 68.41 | 98.64 | 66.39 | 53.41 | 79.37 | 78.87 | 73.59 |
| ROA(%) | -0.6 | 124.92 | 18.25 | 4.32 | 2.39 | 1.54 | 1.66 | 0.63 | 1.75 | 1.05 | 3.58 |
| ROE(%) | -1.02 | 125.8 | 18.47 | 4.41 | 2.44 | 1.56 | 1.68 | 0.64 | 1.78 | 1.07 | 3.62 |
| ROCE(%) | -0.61 | 124.95 | 18.43 | 4.45 | 2.6 | 1.73 | 1.88 | 0.78 | 1.86 | 1.14 | 3.69 |
| Receivable days | 0 | 43.8 | 55.17 | 0 | 233.6 | 512.37 | 577.12 | 848.13 | 1192.36 | 1630.41 | 888.1 |
| Inventory Days | 0 | 97.88 | 69.61 | 98.08 | 87.85 | 188.39 | 200.57 | 201.1 | 205.59 | 256.43 | 107.96 |
| Payable days | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| PER(x) | 0 | 0 | 22 | 679.59 | 1040.72 | 1446.37 | 1526.73 | 3296.75 | 0 | 0 | 0 |
| Price/Book(x) | 0 | 0 | 2.39 | 29.38 | 25.06 | 22.33 | 25.4 | 21.03 | 0 | 0 | 0 |
| Dividend Yield(%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EV/Net Sales(x) | 0 | 0.57 | 13.63 | 242.49 | 236.97 | 356.75 | 343.1 | 332.72 | 9.81 | 13.06 | 6.85 |
| EV/Core EBITDA(x) | -147.6 | 0.52 | 15.07 | 321.01 | 338.13 | 351.75 | 496.53 | 598.21 | 12.12 | 16.17 | 9.19 |
| Net Sales Growth(%) | 0 | 0 | 64.32 | -27.31 | -10.61 | -39.64 | 20.91 | -13.87 | -17.73 | -25.03 | 90.55 |
| EBIT Growth(%) | -150 | 0 | -2.23 | -57.85 | -39.74 | -32.3 | 11.04 | -57.85 | 141.33 | -37.95 | 231.87 |
| PAT Growth(%) | -150 | 0 | -2.31 | -58.49 | -42.95 | -34.69 | 10.27 | -61.22 | 181.45 | -39.26 | 247.42 |
| EPS Growth(%) | -150 | 0 | -78.58 | -58.51 | -42.89 | -34.62 | 10.03 | -61.32 | 182.31 | -39.23 | 247.39 |
| Debt/Equity(x) | 0.68 | 0 | 0 | 0.01 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Ratio(x) | 98.4 | 7394.4 | 76.31 | 27.43 | 219.48 | 192.77 | 52.59 | 47.41 | 42.49 | 53.95 | 92.99 |
| Quick Ratio(x) | 98.4 | 5840 | 69 | 25.7 | 210.98 | 180.16 | 49.55 | 45.46 | 40.91 | 52.19 | 91.04 |
| Interest Cover(x) | 0 | 0 | 7949.78 | 3936.3 | 3272.56 | 63.08 | 150.94 | 28.83 | 369.11 | 1956.75 | 2897.08 |
| Total Debt/Mcap(x) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| # | Mar 2020 | Sep 2020 | Mar 2021 | Sep 2021 | Mar 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 21.93 | 21.93 | 21.93 | 21.93 | 21.93 | 21.93 | 21.93 | 21.93 | 21.93 | 21.93 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 78.07 | 78.07 | 78.07 | 78.07 | 78.07 | 78.07 | 78.07 | 78.07 | 78.07 | 78.07 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Mar 2020 | Sep 2020 | Mar 2021 | Sep 2021 | Mar 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 3.5 | 3.5 | 3.5 | 3.5 | 3.5 | 3.5 | 3.5 | 3.5 | 3.5 | 3.5 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 12.46 | 12.46 | 12.46 | 12.46 | 12.46 | 12.46 | 12.46 | 12.46 | 12.46 | 12.46 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 15.96 | 15.96 | 15.96 | 15.96 | 15.96 | 15.96 | 15.96 | 15.96 | 15.96 | 15.96 |
* The pros and cons are machine generated.
You May Also Know About
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.
